1. Home
  2. ATOS vs CHCI Comparison

ATOS vs CHCI Comparison

Compare ATOS & CHCI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ATOS
  • CHCI
  • Stock Information
  • Founded
  • ATOS 2009
  • CHCI 1985
  • Country
  • ATOS United States
  • CHCI United States
  • Employees
  • ATOS N/A
  • CHCI N/A
  • Industry
  • ATOS Biotechnology: Pharmaceutical Preparations
  • CHCI Building operators
  • Sector
  • ATOS Health Care
  • CHCI Real Estate
  • Exchange
  • ATOS Nasdaq
  • CHCI Nasdaq
  • Market Cap
  • ATOS 107.2M
  • CHCI 100.9M
  • IPO Year
  • ATOS 2012
  • CHCI 2004
  • Fundamental
  • Price
  • ATOS $0.79
  • CHCI $18.56
  • Analyst Decision
  • ATOS Strong Buy
  • CHCI
  • Analyst Count
  • ATOS 3
  • CHCI 0
  • Target Price
  • ATOS $6.17
  • CHCI N/A
  • AVG Volume (30 Days)
  • ATOS 502.4K
  • CHCI 34.5K
  • Earning Date
  • ATOS 08-12-2025
  • CHCI 11-06-2025
  • Dividend Yield
  • ATOS N/A
  • CHCI N/A
  • EPS Growth
  • ATOS N/A
  • CHCI 83.14
  • EPS
  • ATOS N/A
  • CHCI 1.51
  • Revenue
  • ATOS N/A
  • CHCI $55,514,000.00
  • Revenue This Year
  • ATOS N/A
  • CHCI N/A
  • Revenue Next Year
  • ATOS N/A
  • CHCI N/A
  • P/E Ratio
  • ATOS N/A
  • CHCI $12.28
  • Revenue Growth
  • ATOS N/A
  • CHCI 18.44
  • 52 Week Low
  • ATOS $0.55
  • CHCI $6.31
  • 52 Week High
  • ATOS $1.66
  • CHCI $18.99
  • Technical
  • Relative Strength Index (RSI)
  • ATOS 50.57
  • CHCI 70.50
  • Support Level
  • ATOS $0.81
  • CHCI $15.22
  • Resistance Level
  • ATOS $0.80
  • CHCI $18.51
  • Average True Range (ATR)
  • ATOS 0.03
  • CHCI 1.14
  • MACD
  • ATOS 0.01
  • CHCI 0.12
  • Stochastic Oscillator
  • ATOS 82.86
  • CHCI 89.51

About ATOS Atossa Therapeutics Inc.

Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.

About CHCI Comstock Holding Companies Inc.

Comstock Holding Co Inc is a developer and manager of mixed-use and transit-oriented properties with operations that are majorly focused on the Washington, D.C. metropolitan area. It provides a range of services such as asset management, property management, development and construction management, and other real estate-related services to its asset-owning clients, composed predominantly of institutional real estate investors, high net worth family offices, financial institutions, and governmental bodies seeking to enhance their surrounding communities by developing real estate through public-private partnerships.

Share on Social Networks: